Experimental combo therapy targets Hard-to-Treat HER2+ cancers
NCT ID NCT06027983
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tests whether combining trastuzumab (a targeted antibody) with specially engineered immune cells (CAR T-cells) can safely control HER2-positive advanced breast cancer and other solid tumors. About 36 adults will receive the combination after a short chemotherapy course to prepare their immune system. The main goals are to check safety and see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trastuzumab and chimeric receptor T-cells (CAR T-cells)
- What this could lead to
- If it works, this could offer a new treatment option for people with HER2-positive cancers that have stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial with only 36 participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2+ ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug combo keep advanced breast cancer in check?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- New national registry aims to unlock secrets of Ultra-Rare childhood cancers
- New drug targets rare genetic cancers in early trial
- Experimental combo targets Hard-to-Treat bone cancer
- New pill JAB-3312 tested in patients with advanced cancers